Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alcon has announced that the FDA has approved Patanase nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.
Subscribe to our email newsletter
The FDA approval of Patanase nasal spray was based primarily on multiple clinical studies for the evaluation of safety, efficacy and onset of action. The results of these clinical studies were that patients treated with Patanase, two sprays per nostril, twice daily, demonstrated significantly greater decreases in total nasal symptom scores (TNSS) compared to the placebo nasal spray.
Patanase nasal spray, an extension to the company’s market-leading ocular allergy product line, will be available in May, 2008.
Kevin Buehler, Alcon’s senior vice president, global markets and chief marketing officer, said: “We look forward to providing doctors the opportunity to prescribe Patanase to their patients who need and want a fast-acting nasal spray that quickly relieves symptoms.”